Taken together, these findings suggest that modulation of ABCB1 and ABCC10 activities by specific and reversal inhibitors may have a significant clinical value in management of a broad spectrum of human malignancies that are treated with taxanes, based on action in eliminating these drugs from tumor tissues. The gene discussed is ABCC10; the disease is neoplasm.